JP2022511498A5 - - Google Patents

Info

Publication number
JP2022511498A5
JP2022511498A5 JP2021531818A JP2021531818A JP2022511498A5 JP 2022511498 A5 JP2022511498 A5 JP 2022511498A5 JP 2021531818 A JP2021531818 A JP 2021531818A JP 2021531818 A JP2021531818 A JP 2021531818A JP 2022511498 A5 JP2022511498 A5 JP 2022511498A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cdk4
resistant
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531818A
Other languages
English (en)
Japanese (ja)
Other versions
JP7504097B2 (ja
JP2022511498A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065005 external-priority patent/WO2020118213A1/en
Publication of JP2022511498A publication Critical patent/JP2022511498A/ja
Publication of JP2022511498A5 publication Critical patent/JP2022511498A5/ja
Application granted granted Critical
Publication of JP7504097B2 publication Critical patent/JP7504097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531818A 2018-12-06 2019-12-06 Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法 Active JP7504097B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776323P 2018-12-06 2018-12-06
US62/776,323 2018-12-06
PCT/US2019/065005 WO2020118213A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer resistant to cdk4/6 inhibitors

Publications (3)

Publication Number Publication Date
JP2022511498A JP2022511498A (ja) 2022-01-31
JP2022511498A5 true JP2022511498A5 (https=) 2022-12-19
JP7504097B2 JP7504097B2 (ja) 2024-06-21

Family

ID=69063871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531818A Active JP7504097B2 (ja) 2018-12-06 2019-12-06 Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法

Country Status (17)

Country Link
US (2) US20210330612A1 (https=)
EP (1) EP3890834A1 (https=)
JP (1) JP7504097B2 (https=)
KR (1) KR20210100137A (https=)
CN (2) CN113164779A (https=)
AU (1) AU2019395093B2 (https=)
BR (1) BR112021010110A2 (https=)
CA (1) CA3121930A1 (https=)
EA (1) EA202191283A1 (https=)
IL (1) IL283659A (https=)
JO (1) JOP20210137B1 (https=)
MA (1) MA54388A (https=)
MX (1) MX2021006411A (https=)
PH (1) PH12021551319A1 (https=)
SG (1) SG11202105531XA (https=)
UA (1) UA130036C2 (https=)
WO (1) WO2020118213A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
AU2021401580A1 (en) * 2020-12-14 2023-06-22 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN116327894A (zh) * 2023-04-10 2023-06-27 上海市第一妇婴保健院 一种治疗kras突变的卵巢癌的组合药物及其应用
WO2025202871A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR20250152679A (ko) * 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
JP7481115B2 (ja) * 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
MX2020013713A (es) * 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.

Similar Documents

Publication Publication Date Title
JP2022511498A5 (https=)
JP2018518529A5 (https=)
RU2017140676A (ru) Способы лечения рака
JP2018514549A5 (https=)
Schlichtig et al. New oral anti-cancer drugs and medication safety
Craig et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities
JPWO2023140329A5 (https=)
WO2024211271A1 (en) Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition
JP7504097B2 (ja) Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法
CN108778276A (zh) 用于治疗flt3突变型增殖性疾患相关突变的克莱拉尼
Sereno et al. A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation
Shah et al. Hormone receptor–positive/human epidermal growth receptor 2–negative metastatic breast cancer in young women: emerging data in the era of molecularly targeted agents
Giopanou et al. RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies
Guan et al. Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis
CN119546292A (zh) 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法
CN102770026B (zh) 组合
Davies et al. Targeted therapy for melanoma-a primer
JP2022511497A5 (https=)
Lai et al. Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report
Heidenreich et al. Targeted therapy in patients with metastatic male germ cell tumors
RU2021116293A (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
JP6148320B2 (ja) 組合せ
NZ737822B2 (en) Methods of treating cancer
RU2021116084A (ru) Способы лечения рака на моделях, имеющих мутации esr1
US20220226338A1 (en) Methods of Treating Cancer Using CHK1 Inhibitors